Strategic Partnerships mProbe actively collaborates with partners like ACT Genomics, CureMatch, ProPhase Labs, and Spesana, presenting clear cross-sell and co-development opportunities for clinical cancer proteomics, AI-powered precision medicine, and translational diagnostics across Asia and other regions.

Clinical Expansion With four product lines spanning Precision Cancer Care, Maternal/Child Care, Health and Wellness, and Healthcare Analytics, there is substantial opportunity to upsell integrated multi-omic and AI solutions to oncology, obstetrics, and hospital systems seeking end-to-end precision medicine and predictive risk insights.

Healthcare Analytics Channel Leverage HBI Solutions’ ML/AI platforms to target hospitals, regional health systems, and insurers seeking cost reductions and quality improvements, positioning mProbe as a data-driven partner for risk prediction, care optimization, and population health management.

Global Market Entry ACT Genomics partnership indicates readiness to deploy in Asia; sales efforts can focus on regional expansion, regulatory-ready CLIA diagnostics, and collaborations with local labs to scale molecular diagnostics and proteomics services internationally.

Clinical Value Proposition Emphasize pre-symptomatic and individualized care capabilities to oncologists, obstetricians, and preventive medicine programs, highlighting the ability to influence treatment selection, preterm birth prevention, and chronic disease risk management through proprietary AI and multi-omic tests.